| dc.contributor.advisor | Amanzada, Ahmad PD Dr. | |
| dc.contributor.author | Bathe, Anna Luisa | |
| dc.date.accessioned | 2021-02-22T08:11:41Z | |
| dc.date.issued | 2021-02-22 | |
| dc.identifier.uri | http://hdl.handle.net/21.11130/00-1735-0000-0005-157A-B | |
| dc.identifier.uri | http://dx.doi.org/10.53846/goediss-8437 | |
| dc.identifier.uri | http://dx.doi.org/10.53846/goediss-8437 | |
| dc.language.iso | deu | de |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject.ddc | 610 | de |
| dc.title | Einfluss von fäkalem Calprotectin auf klinische Entscheidungen bei Patienten mit Morbus Crohn und Colitis ulcerosa | de |
| dc.type | doctoralThesis | de |
| dc.title.translated | Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis | de |
| dc.contributor.referee | Amanzada, Ahmad PD Dr. | |
| dc.date.examination | 2021-02-23 | |
| dc.description.abstracteng | Faecal calprotectin (FC) seems to be the best available biomarker for the detection of intestinal
inflammation in patients with inflammatory bowel disease (IBD). The aim of this study is
to clarify whether the measurement of FC has changed the number of ultrasound and endoscopic
procedures, drug modifications, as well as FC re-measurements in IBD patients. This retrospective study included 254 IBD patients. Clinical consequences such
as carrying out abdominal ultrasound, endoscopy, drug modification or FC re-measurement
at the next ambulatory presentation or during in-patient stay were collected. Statistical analysis
was performed to determine the association between clinical decision-making and
patient’s characteristics, especially FC value. In CD patients with high FC values significantly
increased numbers of abdominal ultrasounds, endoscopies and FC re-measurements
were noted. In UC patients with high FC values significantly increased numbers of
abdominal ultrasounds, drug modifications and FC re-measurements were noted. Measurement of FC may alter physician’s clinical decision-making in IBD patients beside
other clinical and diagnostic parameters. Further prospective and survey studies are warranted to evaluate the influence of FC measurement in the daily clinical decisionmaking. | de |
| dc.contributor.coReferee | Hilgers, Reinhard Prof. Dr. | |
| dc.contributor.thirdReferee | Oppermann, Martin Prof. Dr. | |
| dc.subject.eng | Faecal calprotectin | de |
| dc.identifier.urn | urn:nbn:de:gbv:7-21.11130/00-1735-0000-0005-157A-B-6 | |
| dc.affiliation.institute | Medizinische Fakultät | de |
| dc.subject.gokfull | Innere Medizin - Allgemein- und Gesamtdarstellungen (PPN619875747) | de |
| dc.description.embargoed | unknown | |
| dc.identifier.ppn | 1749127288 | |